These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34740228)

  • 1. Doravirine: its role in HIV treatment.
    Stockdale AJ; Khoo S
    Curr Opin HIV AIDS; 2022 Jan; 17(1):4-14. PubMed ID: 34740228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
    Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
    J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
    Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
    Soulie C; Santoro MM; Charpentier C; Storto A; Paraskevis D; Di Carlo D; Gennari W; Sterrantino G; Zazzi M; Perno CF; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG
    J Antimicrob Chemother; 2019 Mar; 74(3):614-617. PubMed ID: 30476106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
    Rhee SY; Schapiro JM; Saladini F; Zazzi M; Khoo S; Shafer RW
    AIDS Res Ther; 2023 Feb; 20(1):8. PubMed ID: 36750835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doravirine: First Global Approval.
    Deeks ED
    Drugs; 2018 Oct; 78(15):1643-1650. PubMed ID: 30341683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doravirine: A Return of the NNRTI Class?
    Blevins SR; Hester EK; Chastain DB; Cluck DB
    Ann Pharmacother; 2020 Jan; 54(1):64-74. PubMed ID: 31416335
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
    Steegen K; Moorhouse M; Wensing AM; Venter WD; Hans L
    J Int AIDS Soc; 2021 May; 24(5):e25706. PubMed ID: 33943000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doravirine: a review.
    Colombier MA; Molina JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):308-314. PubMed ID: 29794817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.